Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401517286> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2401517286 endingPage "4692" @default.
- W2401517286 startingPage "4685" @default.
- W2401517286 abstract "Background: A phase II study of a cisplatin/paclitaxel combination given on a weekly schedule in the front-line treatment of non-small cell lung cancer (NSCLC) is reported. Patients and Methods: Treatment consisted of an intravenous infusion of cisplatin, 25 mg/m 2 , and paclitaxel, 80 mg/m 2 , every week. Chemotherapy was continued until completion of a 22-week treatment plan, disease progression, persistent toxicity, or patient refusal. Results: Seventy-nine patients entered the study. The median number of infusions per patient was 14 (range 0-22). The median dose-intensity was 75% of that projected. Toxicity was generally acceptable, and never life-threatening. Seven complete responses (pathologically documented in 4 patients) and 27 partial responses were observed for an overall response rate of 43%. The estimated median survival and median time to progression was 55 (95% CI: 38-71) and 37 weeks (95% CI: 31-44), respectively. Conclusion: In our experience, the weekly combination of cisplatin and paclitaxel is well tolerated, active and associated with remarkably long survivals. Today, lung cancer represents a major public health concern worldwide, accounting for about 12% of all new cancers in both sexes (1-3). Non-small cell lung cancers (NSCLC), including the varieties of adenocarcinomas, squamous cell and large cell carcinomas of the bronchus, represent 75-80% of all histotypes of lung cancer. Most of the patients with NSCLC present an incurable stage of disease, and 5-year survival across all stages is about 12%" @default.
- W2401517286 created "2016-06-24" @default.
- W2401517286 creator A5038434491 @default.
- W2401517286 creator A5065209295 @default.
- W2401517286 date "2005-11-01" @default.
- W2401517286 modified "2023-09-24" @default.
- W2401517286 title "Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study." @default.
- W2401517286 cites W138119981 @default.
- W2401517286 cites W1580788756 @default.
- W2401517286 cites W1935885922 @default.
- W2401517286 cites W1963786241 @default.
- W2401517286 cites W1973347913 @default.
- W2401517286 cites W1974008536 @default.
- W2401517286 cites W1975173161 @default.
- W2401517286 cites W1979300931 @default.
- W2401517286 cites W1996285570 @default.
- W2401517286 cites W1998951921 @default.
- W2401517286 cites W2026876189 @default.
- W2401517286 cites W2031750715 @default.
- W2401517286 cites W2057679671 @default.
- W2401517286 cites W2060985892 @default.
- W2401517286 cites W2071698089 @default.
- W2401517286 cites W2103012467 @default.
- W2401517286 cites W2103151868 @default.
- W2401517286 cites W2111248638 @default.
- W2401517286 cites W2120272649 @default.
- W2401517286 cites W2124435059 @default.
- W2401517286 cites W2129793485 @default.
- W2401517286 cites W2133175910 @default.
- W2401517286 cites W2154651004 @default.
- W2401517286 cites W2166399931 @default.
- W2401517286 cites W2167805334 @default.
- W2401517286 cites W2268190867 @default.
- W2401517286 cites W2504684570 @default.
- W2401517286 cites W3145077989 @default.
- W2401517286 cites W2519810771 @default.
- W2401517286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16334161" @default.
- W2401517286 hasPublicationYear "2005" @default.
- W2401517286 type Work @default.
- W2401517286 sameAs 2401517286 @default.
- W2401517286 citedByCount "1" @default.
- W2401517286 crossrefType "journal-article" @default.
- W2401517286 hasAuthorship W2401517286A5038434491 @default.
- W2401517286 hasAuthorship W2401517286A5065209295 @default.
- W2401517286 hasConcept C121608353 @default.
- W2401517286 hasConcept C126322002 @default.
- W2401517286 hasConcept C141071460 @default.
- W2401517286 hasConcept C143998085 @default.
- W2401517286 hasConcept C2776256026 @default.
- W2401517286 hasConcept C2776694085 @default.
- W2401517286 hasConcept C2777292972 @default.
- W2401517286 hasConcept C2778239845 @default.
- W2401517286 hasConcept C2778822529 @default.
- W2401517286 hasConcept C29730261 @default.
- W2401517286 hasConcept C31760486 @default.
- W2401517286 hasConcept C71924100 @default.
- W2401517286 hasConcept C90924648 @default.
- W2401517286 hasConceptScore W2401517286C121608353 @default.
- W2401517286 hasConceptScore W2401517286C126322002 @default.
- W2401517286 hasConceptScore W2401517286C141071460 @default.
- W2401517286 hasConceptScore W2401517286C143998085 @default.
- W2401517286 hasConceptScore W2401517286C2776256026 @default.
- W2401517286 hasConceptScore W2401517286C2776694085 @default.
- W2401517286 hasConceptScore W2401517286C2777292972 @default.
- W2401517286 hasConceptScore W2401517286C2778239845 @default.
- W2401517286 hasConceptScore W2401517286C2778822529 @default.
- W2401517286 hasConceptScore W2401517286C29730261 @default.
- W2401517286 hasConceptScore W2401517286C31760486 @default.
- W2401517286 hasConceptScore W2401517286C71924100 @default.
- W2401517286 hasConceptScore W2401517286C90924648 @default.
- W2401517286 hasLocation W24015172861 @default.
- W2401517286 hasLocation W24015172862 @default.
- W2401517286 hasOpenAccess W2401517286 @default.
- W2401517286 hasPrimaryLocation W24015172861 @default.
- W2401517286 hasVolume "25" @default.
- W2401517286 isParatext "false" @default.
- W2401517286 isRetracted "false" @default.
- W2401517286 magId "2401517286" @default.
- W2401517286 workType "article" @default.